ArticleScientific reports2025
Butin inhibits osteoarthritis progression by modulating the Nrf2/HO-1 signaling pathway and inhibiting NF-κB signaling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The current treatment of osteoarthritis is limited to the reliever treatment of anti-inflammatory drugs, and there is still a lack of safe and effective drug treatment. Butin, a flavonoid, has the potential to be a drug candidate due to its excellent anti-inflammatory and antioxidant effects. However, the molecular mechanism of Butin's anti-inflammatory and antioxidant mechanisms is still unclear, so in this study, we explored Butin's role in alleviating osteoarthritis and the role of Butin in regulating the Nrf2/HO1/NF-κB axis of cellular antioxidant defense. We used the MTT test, the EdU test, and flow cytometry (FCM) to validate Butin's effect on IL-1β-induced chondrocyte cell viability. Western blot (WB) was used to detect the Nrf2/HO1/NF-κB axis-related proteins to explore the effect of Butin on the Nrf2/HO1/NF-κB axis. In addition, we used quantitative real-time polymerase chain reaction (qPCR), Elisa, flow cytometry to detect cartilage extracellular matrix characteristic proteins (Aggrecan, Collagen II, MMP13 and ADAMTS5). The results showed that Butin could effectively up-regulate the Nrf2/HO1 axis, reduce NF-κB expression, improve chondrocyte damage, and alleviate the progression of osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.